Levosimendan Kalceks

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer presented as an injectable solution for intravenous use. It treats acute decompensated heart failure and cardiogenic shock in hospitalized patients.

GNH USA supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Levosimendan acts on the cardiovascular system to improve cardiac performance in severe heart failure conditions. - Acute decompensated heart failure: enhances cardiac output and reduces symptoms of congestion. - Cardiogenic shock: provides inotropic support while lowering afterload. - Post‑cardiac surgery low cardiac output: helps restore adequate circulation after surgery.

Levosimendan may cause a range of adverse reactions.

Common Side Effects: - Hypotension: drop in blood pressure, especially during infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of skin. - Arrhythmias: occasional premature beats. - Dizziness: related to blood pressure changes.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular tachycardia: potentially life‑threatening rhythm disturbance. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Anaphylactic reaction: rare but possible allergic response. - Severe arrhythmogenic death: extremely rare fatal rhythm events. - Pulmonary edema: fluid accumulation in lungs.

Levosimendan requires careful monitoring and specific safety measures. - Cardiovascular monitoring: continuous blood pressure and ECG observation during infusion. - Renal impairment: adjust infusion rate and monitor renal function closely. - Electrolyte imbalance: correct potassium and magnesium before administration. - Concomitant vasodilators: use with caution due to additive hypotensive effect. - Pregnancy: safety unknown; avoid unless clearly indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several cardiovascular agents.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilation may cause severe hypotension. - Phosphodiesterase inhibitors (e.g., milrinone): increased risk of arrhythmias. - Beta‑blockers: may blunt the intended inotropic response.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure for additive effects. - Diuretics: watch for electrolyte disturbances, especially potassium. - Calcium channel blockers: may affect vascular response to levosimendan.